Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug ...

The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...

As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...

Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has ...